New Guidelines Advocate for Routine Prostate Cancer Screening for Men Over 50
The American Cancer Society (ACS) has updated its screening recommendations for prostate cancer, urging men to begin routine prostate-specific antigen (PSA) testing at age 50 if they are at average risk. For those considered at higher risk, including Black men and individuals with a family history of prostate cancer, screenings should start at age 45. This significant shift in guidelines reflects emerging evidence that regular PSA testing can reduce the risk of dying from prostate cancer by 13% and enable earlier detection of potentially aggressive forms of the disease.
This latest guidance, published in the journal *CA: A Cancer Journal for Clinicians*, signifies a departure from the ACS’s previous approach, which focused on shared decision-making regarding screening. The organization now emphasizes the importance of routine PSA testing to help combat the rising rates of advanced prostate cancer seen in recent years.
The updated recommendations suggest that men aged 50 to 69 should undergo PSA testing every two years. For men aged 70 to 74, the ACS recommends personalized decision-making regarding screening. If chosen, testing should continue every two years until age 74. Notably, experts also advise that men over 75 should not dismiss the possibility of screening if their individual health circumstances warrant it.
Advancements in MRI technology and biomarker testing are enhancing healthcare providers’ ability to determine the necessity of further testing when PSA levels are elevated. This approach aims to minimize unnecessary biopsies and the potential overtreatment that can result from elevated PSA readings.
The ACS’s previous guidelines, last updated in 2010, called for informed discussions between patients and healthcare providers, largely due to conflicting studies about the benefits and risks of PSA screening. However, more recent long-term studies have provided clearer evidence supporting early detection, prompting the ACS to revise its recommendations.
The updated guidelines are especially relevant given the approximately 3% annual increase in prostate cancer diagnoses in the United States from 2014 to 2022. The rise in advanced-stage diagnoses has highlighted the critical need for regular screenings. The new guidance also draws on findings from the European Randomized Study of Screening for Prostate Cancer, which demonstrated that regular PSA screening significantly reduces mortality rates from the disease.
Healthcare professionals now recommend further testing for men under 70 who have PSA levels of 3 ng/mL or higher, while those aged 70 and older may require additional testing if their levels reach 6.5 ng/mL or above. These cutoffs are based on the understanding that PSA levels can naturally be higher in older men.
Experts believe that increased adherence to these new guidelines could lead to earlier detection of prostate cancer, ultimately improving treatment outcomes. By standardizing the approach to prostate cancer screening, the ACS aims to foster a unified effort in men’s health and enhance the overall effectiveness of cancer care.
